Kemet Unveils Pricing of Secondary Offering of 8.4 Mln Shares

Kemet Unveils Pricing of Secondary Offering of 8.4 Mln Shares

Kemet (KEM) said after market close on Friday that it has unveiled the pricing of a previously announced public secondary offering of 8.4 million shares. The shares offered are subject to issuance upon exercise of a currently outstanding and exercisable warrant held by the selling security holder, K Equity, an affiliate of Platinum Equity Capital Partners II, that will be sold to an exercised by UBS Investment Bank, the underwriter […]

Read More ˃
Gilead Sciences Upgraded to Buy From Hold by Argus on Kite Pharma Deal, Price Target at $100

Gilead Sciences Upgraded to Buy From Hold by Argus on Kite Pharma Deal, Price Target at $100

Gilead Sciences (GILD) received an investment-rating upgrade Thursday to buy from hold from Argus Research following the biopharmaceutical company’s agreement announced earlier this week to acquire Kite Pharma (KITE) for about $11.9 billion. The deal “changes our view of Gilead and its long-term growth prospects, and underscores the company’s ability to expand outside its core area of antiviral drugs,” Argus said as it made the investment-rating upgrade and set a […]

Read More ˃
Gasoline Slides 3%, Crude Prices Slip Too

Gasoline Slides 3%, Crude Prices Slip Too

Gasoline prices traded 3% lower on Friday, beginning September down after a whopping 25% rally in August, while crude futures also fell on the notion that supplies may be adequate despite disruptions to oil refining and drilling from Hurricane Harvey. Viral images and news of gas pumps in Texas running out of fuel took the spot gasoline futures on the New York Mercantile Exchange to two-year highs above $2 a […]

Read More ˃
Insys Therapeutics Says Statements Made in Connection With Arizona AG Investigation of Firm Lack Accuracy

Insys Therapeutics Says Statements Made in Connection With Arizona AG Investigation of Firm Lack Accuracy

Insys Therapeutics (INSY) said Friday that recent statements relating to the Arizona Attorney General’s investigation of the company lack context and factual accuracy. The company said the allegations contained in the AG’s complaint relate to former employees and physicians that are no longer associated with the company and that it will cooperate with the investigation. “By many estimates, the national opioid crisis began more than a decade and a half […]

Read More ˃